Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside
- Market capitalization leaves room for a lot of upside.
- Piper Jaffray believes cardiovascular gene therapy could explode on scene in 2015.
- 350,000-525,000 patient population with Breakthrough Therapy status from FDA.
- Results from Phase 2b trial due in April; the company is ramping up production capacity now.
Sky-mobi Could Double And Still Be Undervalued
- MOBI, with no debt, and enterprise value relative to earnings potential, is dirt cheap.
- Cash per share is half the market cap.
- Explosion in earnings growth in the next 12-months is expected.
- BlackBerry Name Change And Spin-Offs Next?
- Zeltiq Taking Shareholders To Highs With Fat Reduction Methodology
- Atossa Genetics: Pullback In Shares Of Breast Cancer Testing Firm Present Opportunity
- McEwen Mining Poised To Rally Sharply Higher
- Wearable Computing Is Coming - Himax Is One Way To Invest
- Gold And Gold Stocks, Undervalued And Poised To Run
- It's Time For Investors To 'Like' Facebook Stock